I’m reporting from captivity in Agadir, a Moroccan city which I’ve just found out it’s the birth-place of Moncef Slaoui, the newly appointed head of “Operation Warp Speed” , Trump’s mass-vaccination campaign. And the that’s the least disturbing thing I have to tell you.
I probably need protection now, I’m warned, authorities here are not big fans of free speech, people have been arrested for much less. But this isn’t much of a life anyway; all worth it if you spread this knowledge like fire. May the public eye be my protection, if any.
US President Donald Trump selected Moroccan immunology expert Moncef Slaoui to be the head of his administration’s COVID-19 vaccine development team, working on “Operation Warp Speed.”
The Moroccan expert, 60, will serve as the US government’s “therapeutics czar” to help coordinate the development of vaccines and treatments. The role is shared between the US Department of Health and Human Services and the Department of Defense.
Slaoui will be assisted by Army Gen. Gustave Perna, the commander of United States Army Materiel Command.
As I found out, Moncef Slaoui holds at least 14 vaccine invention patents.
Slaoui earned a Ph.D. in molecular biology and immunology from the Free University of Brussels, Belgium, and completed his postdoctoral studies at Harvard Medical School and Tufts University School of Medicine, Boston.
He was the former head of the vaccines division at GlaxoSmithKline (GSK), where he oversaw the development of various vaccines: Rotarix, Synflorix, and Cervarix.
In 2007, he announced plans to establish a neurosciences research group in Shanghai that would employ a thousand scientists and cost $100 million; it failed miserably and ceased operations in August 2017.
In 2008, Slaoui led the $720 million acquisition of Sirtris Pharmaceuticals, which folded in 2013. In 2012, he oversaw GSK’s purchase of Human Genome Sciences for over $3 billion.
In 2015 he won European approval for the world’s first malaria vaccine (Mosquirix).
When he retired from the drugmaker in 2017, GSK was still working on the vaccine for Ebola.
GSK is now working on a COVID-19 vaccine with Sanofi, the French multinational pharma giant.
“Not long after leaving GSK, the enthusiastic and outgoing Slaoui started joining biotech boards, with welcomes at SutroVax, mRNA player Moderna as well as the public outfit Intellia $NTLA, one of a handful of CRISPR/Ca9 gene editing startups dominating the field. Then, a little over a month ago, he dropped off the Intellia crew, citing a conflict but not explaining it.” – Endpoints
But his biggest business move was becoming a partner at Medicxi Capital, a biotechnology venture capital firm in the Philadelphia, Pennsylvania area.
Commenting on his new role as Partner at Medicxi, Dr Slaoui said: “I am looking forward to making an active contribution to selecting and leading investments, and to supporting ambitious entrepreneurs to develop medicines that ultimately make a difference to patients.”
Medicxi has built a highly experienced team and, through the scientific advisory boards (SABs) of each of its funds, has access to some of the most respected names in the pharma industry. As well as Medicxi’s senior team, now including Dr Slaoui, external members and observers on the SABs to Medicxi’s funds included (2017):
- From Novartis:
- Dr Vasant (Vas) Narasimhan, Global Head of Drug Development, Chief Medical Officer and Chief Executive Officer Elect
- Dr Evan Beckman, Global Head of Translational Medicine at NIBR
- Nigel Sheail, Head of Business Development and Licensing
- From Verily Life Sciences:
- Dr Andy Conrad, Chief Executive Officer
- Dr Robert Califf, Advisor and former US FDA Commissioner
- From GSK:
- Dr Patrick Vallance President, R&D
- Dr Paul-Peter Tak Senior Vice President R&D Pipeline, Global Development Leader and Chief Immunology Officer
- From Johnson & Johnson:
- Dr. Paul Stoffels, Executive Vice President, Chief Scientific Officer
- Dr. Bill Hait, Global Head, Janssen Research & Development
- Dr Patrick Verheyen Global Head, Janssen Business Development
Michèle Ollier, co-founder and Partner at Medicxi, said: “Moncef has made a tremendous contribution through his role on our SABs and we look forward to his continued energetic and insightful contribution as a Partner at Medicxi. Our SAB meetings are challenging, insightful and inspiring, and contribute hugely to how we steer and advise our portfolio companies.”
Medicxi is based in London, Geneva and Jersey. The Company’s mission is to invest across the full healthcare continuum. Medicxi was established by the former Index Ventures life sciences team. Medicxi manages the legacy life science portfolio of Index Ventures as well as the new funds launched as Medicxi, Medicxi Ventures 1 (MV1) and Medicxi Growth 1 (MG1) focusing on early-stage and late-stage investments in life sciences.
GSK, Johnson & Johnson and Novartis, three of the world’s largest pharmaceutical companies back Medicxi along with Verily, an Alphabet company. These companies, whilst participating in the SABs of the funds, do not receive any preferential rights to the portfolio companies.
Medicxi’s team has been investing in life sciences for over 20 years and has backed many successful companies, including Genmab (NASDAQ Copenhagen: GEN), PanGenetics (sold to AbbVie), Molecular Partners (SWX: MOLN), XO1 (sold to Janssen) Egalet (NASDAQ: EGLT), Minerva Neurosciences (NASDAQ: NERV) and Versartis (NASDAQ: VSAR).
Since 2017, Slaoui has been also sitting on the board of Moderna, a biotechnology company also pursuing a COVID-19 vaccine, based in Cambridge, Massachusetts.
The problem with Moderna is that it’s financed by Bill Gates to develop RNA vaccines technologies
The other problem, because they always come in pairs:
Trump awarded Moderna almost $0.5Billion from public money a few days before nominating Slaoui. CNN reported on May 18th:
“Valera’s efforts (Moderna subsidiary) have resulted in the demonstration of preclinical efficacy of Moderna’s mRNA-based vaccines in multiple viral disease models, Moderna said.
In the partnership with the Gates Foundation, Valera will apply its mRNA vaccine platform as well as Moderna’s drug platform Messenger RNA Therapeutics™. Designed to produces human proteins, antibodies, and entirely novel protein constructs inside patient cells, the therapeutics are secreted or active intracellularly.” – Genetic Engineering & Biotechnology News
What, you think that’s bad? What if I told you this is the last one in a very long series of collaborations between the two?
Gates, Fauci and Slaoui have long been making and selling scandalous vaccines together. It’s a cartel
Why is no one talking about this chapter of Moncef Slaoui’s career? Well, I am:
I find most relevant this transhumanist project Slaoui worked on with Google from 2016, as reported by Bloomberg:
<<The recent partnership between GlaxoSmithKline (GSK) and Alphabet (Google) further opens the door for development in the biotechnology industry’s experimental “bioelectronics” segment.
Chairman of Vaccines at GlaxoSmithKline Dr. Moncef Slaoui thinks the partnership could create an entirely new industry.
“I think this is a whole new industry as big as the pharmaceutical industry … there’s a whole new world that we’re opening here which is dealing with electrical signals to connect with our biology and changes functioning,” Slaoui told CNBC’s Meg Tirrell on “Squawk Box” Monday morning.
Calling Alphabet’s Verily Life Services a “really exciting partner,” Slaoui says GlaxoSmithKline shares “a very common vision of integrating electronics and big data analytics and technologies with medicines and biology.”
“They bring to us the engineering capabilities, the electronics, the low power technologies and the wireless technologies that are critical to miniaturize these devices, power them and extract information from them,” Slaoui noted.>>
“GSK has been interested in this field for years, and in 2013 announced a $1 million prize for innovative bioelectronics research. In a press statement, GSK’s Moncef Slaoui said: “Many of the processes of the human body are controlled by electrical signals firing between the nervous system and the body’s organs, which may become distorted in many chronic diseases.” He said bioelectronic seeks to “correct the irregular [electrical] patterns found in disease states, using miniaturized devices attached to individual nerves.” – The Verge
And having in mind the technological terror, the transhumanist/eugenicist obsessions brought by the coronavirus policy-makers today, one quote from the same source above hits home. This whole business falls right in the arms of anyone associating the coronavirus pandemic with human microchipping. Slaoui cited animal models as the indicator that bioelectronics can treat chronic diseases with a number of different devices.
The devices themselves are very small, about “the size of a rice grain”, and can “either stimulate or black the electric signals that our brains sense through our nerves to control the functioning of our organs… The limitations are around power as power requires energy and energy means heat and heat doesn’t go well with biology.
It gets weirder
Slaoui rejected reports in late March of his involvement with a US government task force for COVID-19 vaccine development and denied as recently as May 11 any intention to work with the Trump administration.
Morocco World News reported in March 31st:
“The doctor said he has no working arrangements with the US government in a statement to Moroccan French-language newspaper L’Economiste.
Several local news outlets claimed that the former chairman of pharmaceutical giant GlaxoSmithKline (GSK) is part of a task force that is researching a vaccine to clamp down on the spread of the virus.
The international expert is currently a member of the board of directors of American biotechnology company Moderna.
Slaoui explained that he is part of the company’s research and development committee. The committee has received support from federal organizations to help fund the development of a COVID-19 vaccine. “
White House senior adviser Jared Kushner, the son-in-law of President Trump, was among the officials who interviewed Slaoui for the role.
Jared Kushner went there.
Jared Kushner personally picked America’s new “Vaccine Czar” Moncef Slaoui precisely one year after the meeting.
Jared Kushner is a Zionist.
Jared Kushner is Trump’s son law.
To avoid a conflict of interest, Slaoui resigned from the board of the Massachusetts-based biotech firm Moderna, which had been developing a vaccine for the coronavirus.
He stepped down but he didn’t give up his stakes in Moderna, as the Daily Beast reports:
“Slaoui’s ownership of 156,000 Moderna stock options, disclosed in required federal financial filings, sparked concerns about a conflict of interest.
Democratic Massachusetts Senator Elizabeth Warren called Slaoui out over the matter on Twitter: “It is a huge conflict of interest for the White House’s new vaccine czar to own $10 million of stock in a company receiving government funding to develop a COVID-19 vaccine. Dr. Slaoui should divest immediately.”
The company’s shares skyrocketed last month after news broke of the $483 million in federal funding to work on a coronavirus vaccine.
Slaoui could not immediately be reached for comment on the matter.”
Slaoui also sits on the boards of SutroVax, the Biotechnology Innovation Organization, the International AIDS Vaccine Initiative, and the PhRMA Foundation
The Moroccan expert’s main contenders for the position of chief advisor at “Operation Warp Speed” were Algeria’s Elias Zerhouni and US’ Arthur Levinson.
Zerhouni, born in 1951, is an Algerian scientist, radiologist, and biomedical engineer. The expert has held several important positions in a number of institutions, ranging from medical schools to pharmaceutical companies and government task forces.
In 2009, under the Obama administration, Zerhouni served as the first science envoy in the US and worked towards fostering scientific and technological collaboration with other countries.
Between 2011 and 2018, as a final stage in his career, Zerhouni was the President for Global Research and Development at, well, Sanofi.
The third main candidate in the race for Trump’s COVID-19 operation, Arthur Levinson, is an American businessman specialized in biotechnology.
Levinson has served as senior advisor for several companies and institutions, including Swiss healthcare multinational Hoffmann-La Roche, Amyris Biotechnologies, the Memorial Sloan Kettering Cancer Center, the California Institute for Quantitative Biosciences, and Princeton University.
The American businessman is currently the chairman of tech giant Apple and CEO of biotechnology company Calico.
“We will get to [vaccines] eventually, but we’re not there yet. If we want to lift the lockdowns, we need to fully respect them first”
Outlook on the pandemic
During an interview on April 12, Slaoui said he expects life to begin its return to normal at the beginning of 2021 after global leaders rein in the pandemic, adding that he considers his prediction “optimistic.”
He is confident “that due to the high number of COVID-19 cases, clinical studies will reach results quickly.” He believes that “by the end of May or by early June, we will know if some of these drugs work.”
“I am very optimistic that we’ll have several vaccines for COVID-19. However, the problem is not having a vaccine. The problem is producing enough to protect eight billion people,” he continued.
Which is weird, because US Government has just announced same day spending $138mil. to turbo-boost vaccine production, and I’ve published a massive investigation piece on that.
In another interview with Moroccan television channel 2M on April 13, Slaoui forecast that the COVID-19 pandemic will heavily scar the global population.
“I believe that by 2021 our reality will not be completely back to normal but it will be improved,” he argued.
Moncef Slaoui said if the virus continues to spread, there will be no way to control it other than to create a vaccine and administer it on a massive scale.
“We will get to [vaccines] eventually, but we’re not there yet. If we want to lift the lockdowns, we need to fully respect them first,” he explained.
He said countries can phase out lockdowns when there is a proven COVID-19 treatment.
Slaoui acknowledged that there are now hundreds of clinical studies underway in many countries.
He expressed optimism that due to the increasing number of COVID-19 cases, clinical studies will achieve preliminary results quickly. “I believe that by the end of May or by early June, we will know if some of these drugs work.”
Government watchdog Public Citizen on Thursday “condemned the Trump administration’s reported appointment of a former pharmaceutical executive to the White House’s task force aimed at swiftly developing a Covid-19 vaccine as another example of the White House putting management of the pandemic in the hands of private industry. “
“If the Trump administration approaches vaccine development as it has Covid-19 prevention, testing, and treatment, the world may be in for years of more extraordinary pain,” Maybarduk added. “The dangers of global vaccine rationing are profound. No one corporation has the capacity to deliver a vaccine to all the world’s people.”
In March, Trump’s FDA came under fire for awarding monopoly status to Gilead Sciences for Remdesivir, a drug it was developing for Covid-19 treatment. The company backed off its claim after a pressure campaign led by Public Citizen.
“The U.S. government must commit to sharing clinical trial data, patents, and know-how among manufacturers and with the world, to quickly achieve the mountainous scale of production that humanity needs,” the group said.
I saved the best for last. To be continued.
UPDATE: Follow up investigation: Corruption Unltd: GSK and “Trump’s Vaccine Czar”. Sex tapes, dead babies, bribes and prostitutes
Everything makes even more sense if you also read the first part of this series of articles dedicated to the covid mafia and Operation Warp Speed
To be continued?
Our work and existence, as media and people, is funded solely by our most generous supporters. But we’re not really covering our costs so far, and we’re in dire needs to upgrade our equipment, especially for video production.
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!
! Articles can always be subject of later editing as a way of perfecting them